WHO Clears the First Malaria Treatment Designed for Infants

A long-standing treatment gap has a new response

The World Health Organization has given prequalification approval to the first malaria treatment designed specifically for newborns and infants, marking a notable regulatory milestone in global child health. According to the supplied source text, the treatment is an artemether-lumefantrine formulation tailored to the youngest patients and is the first antimalarial medicine developed specifically for this age group.

That distinction matters because infants have until now been treated using formulations intended for older children. The WHO says that practice carries a greater risk of dosage errors, side effects and toxicity. A medicine built for babies changes the standard from adaptation to direct suitability.

The organization framed the decision as both technical and strategic. In its statement, the WHO said prequalification means the medicine meets international standards of quality, safety and efficacy. It also said the designation should enable public-sector procurement, which is critical for reaching health systems that depend on international purchasing channels.

Why this matters in malaria-endemic regions

The burden behind the announcement is enormous. The WHO estimates there were 282 million malaria cases and 610,000 deaths in 2024 across 80 countries. Africa accounted for 95% of both cases and deaths, and children under five represented three-quarters of malaria deaths on the continent.

Against that backdrop, the new infant formulation is not a marginal update. It targets a vulnerable group that has long sat in a treatment gray zone. The WHO says around 30 million babies are born each year in malaria-endemic areas of Africa. A treatment designed for their physiology and dosing needs could make clinical care safer and more practical at scale.

The significance is therefore both medical and logistical. In many health systems, especially under strain, simpler and more appropriate formulations reduce the room for error. When frontline providers are treating very young children, that matters immediately.

Prequalification is more than a label

The WHO’s prequalification program often receives less public attention than a new drug approval headline, but it can be decisive in global health deployment. The source text notes that 70% of countries do not have regulatory systems robust enough to oversee medicines, vaccines, tests and medical devices. In that context, prequalification functions as a practical gateway for trusted international procurement.

For malaria programs, that means the value of this decision is not limited to scientific validation. It opens a path for donor-backed purchasing and public-sector distribution. Without that step, even a promising treatment can struggle to reach the settings where it is most needed.

This is one reason the announcement deserves attention. It is not only a product story. It is a delivery story. The WHO is effectively saying that a long-missing tool now meets the threshold for broad procurement and use.

A rare piece of progress in a difficult fight

The timing is important because malaria control remains under pressure from multiple directions. The source text says the WHO sees progress being hampered by drug resistance, insecticide resistance, diagnostic failure and sharp reductions in foreign aid spending. Those are not small obstacles. They affect prevention, detection and treatment simultaneously.

Against that landscape, the infant medicine stands out as a concrete gain. WHO Director-General Tedros Adhanom Ghebreyesus linked it to a broader set of advances, including vaccines, diagnostic tests, next-generation mosquito nets and effective medicines adapted for the youngest patients. His message was that malaria is still devastating, but the technical toolkit is getting stronger.

That does not mean the problem is solved. The same WHO statement makes clear that progress still depends on sustained political and financial commitment. New tools only change outcomes if systems can buy them, distribute them and use them consistently.

Why infant-specific treatment changes the conversation

There is also a deeper significance to the approval. Global health efforts often improve first for groups that are easiest to study, regulate and supply. Very young infants can be left behind because they require tighter dosing, more careful formulation and added clinical caution. A medicine specifically built for them signals a move away from that pattern.

In practical terms, infant-specific treatment reduces the need to improvise with medicines intended for older children. In strategic terms, it says that closing last-mile treatment gaps is becoming part of the mainstream malaria agenda rather than an afterthought.

That shift matters because the deadliest inequities in infectious disease are often concentrated in the earliest months of life. The WHO decision does not erase those inequities, but it does create a better tool for addressing one of them.

The next test is access

The strongest measure of this announcement will not be the wording of the approval. It will be uptake. Prequalification creates the conditions for procurement, but governments, suppliers and funders still have to move the medicine into clinics and communities.

Even so, the policy signal is strong. For malaria-endemic countries, donors and child-health programs, the WHO has now validated a treatment category that previously did not exist in this form. For families and providers, that means the youngest patients no longer have to rely exclusively on scaled-down solutions built for older children.

• The WHO has prequalified the first malaria treatment designed specifically for newborns and infants.
• The treatment is an artemether-lumefantrine formulation tailored to the youngest patients.
• The agency says the move should support public procurement and help close a major treatment gap in Africa.

This article is based on reporting by Medical Xpress. Read the original article.